Jan Maciej Zaucha
YOU?
Author Swipe
View article: Metabolic Interactions in the Tumor Microenvironment of Classical Hodgkin Lymphoma: Implications for Targeted Therapy
Metabolic Interactions in the Tumor Microenvironment of Classical Hodgkin Lymphoma: Implications for Targeted Therapy Open
Classical Hodgkin lymphoma (cHL) is a biologically and clinically unique malignancy characterized by rare Hodgkin and Reed–Sternberg (HRS) cells surrounded by a dense and diverse inflammatory infiltrate. These malignant cells actively resh…
View article: Retrospective analysis of primary pulmonary lymphoma cases from Polish Lymphoma Research Group centers reveals associations between initial symptoms and outcomes
Retrospective analysis of primary pulmonary lymphoma cases from Polish Lymphoma Research Group centers reveals associations between initial symptoms and outcomes Open
View article: Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study
Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 study Open
View article: Vaccination of adult patients with hematological malignancies, patients with asplenia and patients with nocturnal paroxysmal hemoglobinuria — guidelines of PTHiT and the Infectious Diseases Working Group of PALG
Vaccination of adult patients with hematological malignancies, patients with asplenia and patients with nocturnal paroxysmal hemoglobinuria — guidelines of PTHiT and the Infectious Diseases Working Group of PALG Open
Infections are among the most common causes of morbidity and mortality in patients with hematological malignancies, and proper immunization can significantly reduce their incidence. This aim was to present a review of current data on the r…
View article: 357 | A SHORT (x3) NIVOLUMAB BEFORE BGD CHEMOTHERAPY IMPROVES THE REMISSION RATE IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: N‐BURGUND TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP
357 | A SHORT (x3) NIVOLUMAB BEFORE BGD CHEMOTHERAPY IMPROVES THE REMISSION RATE IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: N‐BURGUND TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP Open
View article: 411 | THE SEARCH FOR BASELINE IMAGING PREDICTIVE FACTORS OF REFRACTORINESS TO ABVD IN THE LOW AND VERY LOW RISK PATIENTS WITH EARLY STAGES HL OF THE RAFTING TRIAL
411 | THE SEARCH FOR BASELINE IMAGING PREDICTIVE FACTORS OF REFRACTORINESS TO ABVD IN THE LOW AND VERY LOW RISK PATIENTS WITH EARLY STAGES HL OF THE RAFTING TRIAL Open
View article: 152 | GLOFITAMAB+R‐CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED LARGE B‐CELL LYMPHOMA DEFINED AS HIGH RISK BY CIRCULATING TUMOR DNA (ctDNA) DYNAMICS: PRIMARY RESULTS
152 | GLOFITAMAB+R‐CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED LARGE B‐CELL LYMPHOMA DEFINED AS HIGH RISK BY CIRCULATING TUMOR DNA (ctDNA) DYNAMICS: PRIMARY RESULTS Open
View article: 417 | TMTV < THAN 32.5 mL IMPAIRS THE SUCCESSFUL DETECTION OF ctDNA IN EARLY‐STAGE HODGIN LYMPHOMA PATIENTS—THE PRELIMINARY REPORT FROM THE RAFTING TRIAL
417 | TMTV < THAN 32.5 mL IMPAIRS THE SUCCESSFUL DETECTION OF ctDNA IN EARLY‐STAGE HODGIN LYMPHOMA PATIENTS—THE PRELIMINARY REPORT FROM THE RAFTING TRIAL Open
View article: 359 | UPDATED RESULTS FROM KEYNOTE‐B68: PEMBROLIZUMAB EVERY 6 WEEKS IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA OR PRIMARY MEDIASTINAL B‐CELL LYMPHOMA
359 | UPDATED RESULTS FROM KEYNOTE‐B68: PEMBROLIZUMAB EVERY 6 WEEKS IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA OR PRIMARY MEDIASTINAL B‐CELL LYMPHOMA Open
View article: A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA
A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA Open
This study analyzed the genetics of classic Hodgkin lymphoma (cHL) by using circulating tumor DNA (ctDNA). Two genetic subtypes were identified, differing in genetic instability mechanisms: one subtype (64% of cases) showed a higher mutati…
View article: Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS Open
Higher-risk myelodysplastic syndrome (HR-MDS) with RARA gene overexpression is a subset of patients (pts) with an actionable target for tamibarotene, an oral and a selective retinoic acid receptor-α (RAR-α) agonist. Tamibarotene with azaci…
View article: Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group
Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group Open
Background: The implementation of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) has brought a significant improvement in the prognosis for CML patients and a decrease in the number of patients requiri…
View article: Efficiency and Safety of Brentuximab Vedotine as a Salvage Treatment Before Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: Retrospective Study
Efficiency and Safety of Brentuximab Vedotine as a Salvage Treatment Before Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: Retrospective Study Open
Background There is no strong evidence supporting brentuximab vedotine (BV) efficacy as a salvage regimen for relapsed/refractory Hodgkin’s lymphoma (R/R HL) patients before autologous hematopoietic cell transplantation (auto‐HCT). Methods…
View article: Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study Open
PURPOSE Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) have a poor prognosis. The phase I/II NP30179 study (ClinicalTrials.gov identifier: NCT03075696 ) evaluated glofitamab monotherapy in patients with R/R B-cell lymph…
View article: Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on behalf of the Polish Adult Leukaemia Group
Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on behalf of the Polish Adult Leukaemia Group Open
Background: The implementation of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) has brought a significant improvement in the prognosis for CML patients and a decrease in the number of patients requiri…
View article: Stem Cell Mobilization Performed with Different Doses of Cytarabine in Plasma Cell Myeloma Patients Relapsing after Previous Autologous Hematopoietic Cell Transplantation—A Multicenter Report by the Polish Myeloma Study Group
Stem Cell Mobilization Performed with Different Doses of Cytarabine in Plasma Cell Myeloma Patients Relapsing after Previous Autologous Hematopoietic Cell Transplantation—A Multicenter Report by the Polish Myeloma Study Group Open
Salvage autologous hematopoietic cell transplantation (auto-HCT) may be used to treat relapse of plasma cell myeloma occurring after previous auto-HCT. When an insufficient number of hematopoietic stem cells have been stored from the initi…
View article: International cooperation to secure access of patients in Ukraine to cellular therapies in conditions of Russian aggression
International cooperation to secure access of patients in Ukraine to cellular therapies in conditions of Russian aggression Open
View article: Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, dexamethasone or lenalidomide alone
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, dexamethasone or lenalidomide alone Open
View article: Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma
Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma Open
Mass spectrometry (MS) can detect multiple myeloma–derived monoclonal proteins in the peripheral blood (PB) with high sensitivity, potentially serving as a PB assay for measurable residual disease (MRD). This study evaluated the significan…
View article: Effective treatment of Clostridioides difficile infection improves survival and affects graft-versus-host disease: a multicenter study by the Polish Adult Leukemia Group
Effective treatment of Clostridioides difficile infection improves survival and affects graft-versus-host disease: a multicenter study by the Polish Adult Leukemia Group Open
View article: The Acquisition of Complement-Dependent Cytotoxicity by the Type II Anti-CD20 Therapeutic Antibody Obinutuzumab
The Acquisition of Complement-Dependent Cytotoxicity by the Type II Anti-CD20 Therapeutic Antibody Obinutuzumab Open
Rituximab, a prototypic anti-CD20 mAb, and the third-generation anti-CD20 mAb obinutuzumab differ in their ability to activate the complement system. According to recent studies, this contrast stems from the architecture of the antigen–ant…
View article: The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review
The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review Open
Primary refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) and mixed phenotype myeloid/T-cell acute leukemia have dismal prognoses. New treatment approaches, preferably targeting specific leukemic aberrations to overcome re…
View article: Incidence and Role of Recipient-Specific Antibodies in Allogeneic Hematopoietic Cell Transplantation from Mismatched Related Donors
Incidence and Role of Recipient-Specific Antibodies in Allogeneic Hematopoietic Cell Transplantation from Mismatched Related Donors Open
High titer of donor-specific antibodies (DSAs) increases the risk of graft rejection after mismatched related hematopoietic cell transplantation (HCT). There are no data regarding the incidence of anti-HLA recipient-specific antibodies (RS…
View article: Impact of Clostridioides difficile infection on survival and graft-versus-host disease after allogeneic hematopoietic cell transplantation: a multicenter study on behalf of the Polish Adult Leukemia Group
Impact of Clostridioides difficile infection on survival and graft-versus-host disease after allogeneic hematopoietic cell transplantation: a multicenter study on behalf of the Polish Adult Leukemia Group Open
Clostridioides difficile infection (CDI) is the most common cause of infectious diarrhea after allogeneic hematopoietic cell transplantation (allo-HCT). The impact of CDI and its treatment on allo-HCT outcomes and graft-versus-host disease…
View article: Identification of novel genetic loci for risk of multiple myeloma by functional annotation
Identification of novel genetic loci for risk of multiple myeloma by functional annotation Open
View article: Identification of novel genetic loci for risk of multiple myeloma by functional annotation
Identification of novel genetic loci for risk of multiple myeloma by functional annotation Open
Multiple myeloma (MM) is one of the most common hematological malignancies, accounting for 20% of all newly diagnosed hematological cancers [1]. The most recent data from Cancer Today show that in 2020 the number of new MM cases was 176,40…
View article: Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 <scp>ATLAS</scp> trial
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 <span>ATLAS</span> trial Open
Summary Previous studies suggest that postautologous stem cell transplant (ASCT) recovery of polyclonal immunoglobulin from immunoparesis in patients with multiple myeloma is a positive prognostic marker. We performed a longitudinal analys…
View article: MCL-467 Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma
MCL-467 Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma Open
View article: POSTER: MCL-467 Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma
POSTER: MCL-467 Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma Open
View article: POSTER: AML-050 Evaluation of Colonization and Infection Epidemiology in Allogeneic Stem Cell Transplantation Recipients: A Prospective, Multicenter Study
POSTER: AML-050 Evaluation of Colonization and Infection Epidemiology in Allogeneic Stem Cell Transplantation Recipients: A Prospective, Multicenter Study Open